A biomarker test to measure progression for Parkinson's Disease is available in the US before 2029
Health & MedicineOne-Off2yManifold MarketsNo KYCVerified resolution dataFairly calibratedCurrent community forecastYes 71.7%
Forecasters
6
Question type
binary
Methodology
Play-money forecasting platform
Source type
Forecast
Market data
Updated 16 hours ago
StaleApr 25, 23, 4:13 PM UTCJan 2, 29, 6:59 AM UTC
Trends
Rules
There will be a test of a biomarker which meaningfully correlates with parkinson's progression for at least a signficant subset (>10% of those diagnosed clinically) of people with Parkinson's disease in the US before 2029
- examples: Patient has classic non-genetic PD from a clinical diagnosis based on symptoms (rigidity, etc.).
- There will be a test which they can take which shows the severity of the disease, and which when given repeatedly can be used to measure how much or less the disease has progressed
